National Asset Management, Inc. Revance Therapeutics, Inc. Transaction History

National Asset Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$12.46 - $27.87 $128,686 - $287,841	-10,328 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$25.78 - $33.21 $12,400 - $15,974	-481 Reduced 4.45%	10,328 $288,000
Q2 2021 Aug 10, 2021	BUY	$26.8 - $31.84 $15,115 - $17,957	564 Added 5.51%	10,809 $321,000
Q1 2021 May 13, 2021	BUY	$24.03 - $29.97 $14,418 - $17,982	600 Added 6.22%	10,245 $287,000
Q3 2020 Nov 09, 2020	BUY	$23.23 - $34.3 $29,734 - $43,904	1,280 Added 15.3%	9,645 $243,000

Q2 2020 Jul 31, 2020	BUY	$12.6 - $26.55 $105,399 - $222,090	8,365 New	8,365 $205,000

214

83.4M

656K

424K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.